Jagsonpal Pharma to acquire 85 percent stake in Aequitas Healthcare for Rs 20.8 Cr

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

JAGSNPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.3%Reaction day

₹230.11

prior close

₹243.69

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.0%+3.2% vs market

Pharmaceuticals peers, median of 165sector+0.8%+3.5% vs sector

On the reaction day the stock moved 3.2 pts more than Nifty Microcap 250 and 3.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.6

10m

+6.0

15m

+6.7

30m

+6.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.3+1.0+3.2+0.8+3.5

Next day

+3.2+1.2+2.0+0.3+2.9

+2.1+2.1+0.0+0.8+1.2

+3.3+1.7+1.6+1.2+2.2

+3.4+1.9+1.4+0.6+2.8

+3.9+1.2+2.6+0.1+3.7

+0.7+1.1-0.4+0.6+0.1

15d

-3.5+1.6-5.2+1.8-5.4

+1.0+0.1+1.0-0.5+1.6

+4.9+6.6-1.8+2.7+2.2

+3.1+5.5-2.3+3.3-0.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Jagsonpal Pharmaceuticals will acquire 85 percent stake in Aequitas Healthcare for Rs 20.8 Cr in cash, funded from internal accruals. Aequitas sells pharma products to hospitals with FY26 revenue of Rs 53.31 Cr. The deal gives Jagsonpal entry into the hospital segment and access to institutional doctor networks. Expected to close by July 15, 2026. Not a related party deal.

Likely market impact

Strategic entry into hospital segment, expanding reach beyond retail. Aequitas adds around Rs 53 Cr revenue. Funded through internal accruals.